Boehringer Ingelheim to Present New Data on PGx NSCLC Drug Afatinib at ASCO Annual Meeting | GenomeWeb

Originally published May 27.

Boehringer Ingelheim will present at an upcoming oncology conference new pharmacogenomic data on its investigational non-small cell lung cancer drug afatinib.

The company will present the data, gathered from an expanded patient cohort enrolled in a Phase Ib study, at the American Society of Clinical Oncology annual meeting in Chicago June 3-7.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.